By using comprehensive lab testing to look at hormones, metabolic function, and other key health markers, these platforms can identify the root cause of your weight challenges
GLP-1 treatment was not statistically significantly different compared to control at reducing the risk of developing dry AMD at one and three years after treatment, but GLP-1 receptor agonists did lower dry AMD risk at five and 10 years after treatment by 9.2% and 14.9%, respectively
PlexusDx Precision Peptide Genetic Test reveals predispositions in GIPR, FTO, and MC4R pathways
Monitoring touchpoints to build into your protocol: Baseline labs and clinical assessment before initiation Follow-up at 4-6 weeks to review tolerability and dosing Progress check at 3 months with reassessment of the care plan Ongoing monitoring as clinically appropriate Be direct with patients: the goal is sustainable weight management, not rapid results
Critical Reviews in Food Science and Nutrition, 59(16), 26882696